172 related articles for article (PubMed ID: 2974879)
1. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
Köhler C; Karlsson-Boethius G
J Neural Transm; 1988; 73(2):87-100. PubMed ID: 2974879
[TBL] [Abstract][Full Text] [Related]
2. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
Köhler C; Karlsson-Boethius G
J Neural Transm; 1989; 76(1):13-28. PubMed ID: 2523467
[TBL] [Abstract][Full Text] [Related]
3. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE
Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255
[TBL] [Abstract][Full Text] [Related]
4. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.
Andersen PH; Nielsen EB
Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):315-8. PubMed ID: 2948372
[TBL] [Abstract][Full Text] [Related]
5. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors.
Köhler C; Hall H; Gawell L
Eur J Pharmacol; 1986 Jan; 120(2):217-26. PubMed ID: 3948920
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
Terai M; Hidaka K; Nakamura Y
Eur J Pharmacol; 1989 Dec; 173(2-3):177-82. PubMed ID: 2576228
[TBL] [Abstract][Full Text] [Related]
7. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.
Köhler C; Hall H; Ogren SO; Gawell L
Biochem Pharmacol; 1985 Jul; 34(13):2251-9. PubMed ID: 4015674
[TBL] [Abstract][Full Text] [Related]
8. Tracer and maximal specific binding of tritiated spiperone or N-n-propylnorapomorphine to quantify dopamine receptors in rat brain regions in vivo.
Van der Werf JF; Sebens JB; Korf J
Life Sci; 1986 Jul; 39(2):155-60. PubMed ID: 3724366
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
[TBL] [Abstract][Full Text] [Related]
10. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390.
Lidow MS; Goldman-Rakic PS; Gallager DW; Rakic P
Neuroscience; 1991; 40(3):657-71. PubMed ID: 2062437
[TBL] [Abstract][Full Text] [Related]
11. Distinct binding patterns of [3H]raclopride and [3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for pet studies.
Bischoff S; Gunst F
J Recept Signal Transduct Res; 1997; 17(1-3):419-31. PubMed ID: 9029505
[TBL] [Abstract][Full Text] [Related]
12. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
George SR; Watanabe M; Seeman P
J Neurochem; 1985 Apr; 44(4):1168-77. PubMed ID: 2579204
[TBL] [Abstract][Full Text] [Related]
14. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
Florijn WJ; Tarazi FI; Creese I
J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
Andersen PH
Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
[TBL] [Abstract][Full Text] [Related]
16. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
Hall H; Wedel I
Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
[TBL] [Abstract][Full Text] [Related]
17. Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.
Köhler C; Haglund L; Ogren SO; Angeby T
J Neural Transm; 1981; 52(3):163-73. PubMed ID: 7198139
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity.
Dewar KM; Montreuil B; Grondin L; Reader TA
J Pharmacol Exp Ther; 1989 Aug; 250(2):696-706. PubMed ID: 2527300
[TBL] [Abstract][Full Text] [Related]
19. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration.
Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2973-7. PubMed ID: 6626267
[TBL] [Abstract][Full Text] [Related]
20. ACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro.
Florijn WJ; De Boer T; Tonnaer JA; Van Nispen JW; Versteeg DH
Eur J Pharmacol; 1991 May; 207(1):43-50. PubMed ID: 1680721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
